LL-37 vs Thymosin Alpha-1
Side-by-side comparison of key properties, dosing, and research.
Immune SupportRecovery & Repair
LL-37Immune SupportAnti-Aging & Longevity
Thymosin Alpha-1- Summary
- LL-37 is the only known human cathelicidin antimicrobial peptide. It kills bacteria, fungi, and viruses by disrupting their membranes, while simultaneously modulating immune responses. Used for antimicrobial protection, immune priming, and wound healing.
- Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide derived from the thymus gland. It is a powerful immune modulator approved in many countries for treating chronic hepatitis B, hepatitis C, and as an adjunct in cancer immunotherapy.
- Half-Life
- Very short (~1–2 hours) in plasma due to protease degradation; topical use bypasses systemic clearance
- 2–3 hours
- Admin Route
- SubQ, Topical, Intranasal
- SubQ
- Research
- —
- —
- Typical Dose
- 100–300 mcg
- 0.8–1.6 mg
- Frequency
- 2–3x per week
- Twice weekly
- Key Benefits
- Broad-spectrum antimicrobial (bacteria, fungi, viruses)
- Promotes wound healing and angiogenesis
- Immune system modulation — enhances innate immunity
- Reduces LPS-mediated endotoxemia
- Anti-biofilm activity against resistant organisms
- Promotes tissue regeneration and keratinocyte migration
- May protect against sepsis
- Enhances T-cell and NK cell activity
- Supports recovery from viral and bacterial infections
- May reduce inflammation systemically
- Supports healthy aging and immune resilience
- Improves vaccine response
- Supports liver health
- May help with chronic fatigue syndrome and post-viral conditions
- Approved in multiple countries for hepatitis B and C treatment
- Side Effects
- Injection site redness and irritation
- Mild inflammatory response at injection site
- Potential pro-inflammatory at high doses
- Rare: fever or flu-like symptoms at initiation
- Injection site irritation
- Mild flu-like symptoms initially (immune activation)
- Fatigue (rare)
- Stacks With
- —
- —